- Home
- FCCO vs AARD Comparison
FCCO vs AARD Comparison
Compare FCCO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCCO
- AARD
- Stock Information
- Founded
- FCCO 1994
- AARD 2017
- Country
- FCCO United States
- AARD United States
- Employees
- FCCO N/A
- AARD N/A
- Industry
- FCCO Major Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- FCCO Finance
- AARD Health Care
- Exchange
- FCCO Nasdaq
- AARD Nasdaq
- Market Cap
- FCCO 182.4M
- AARD 154.9M
- IPO Year
- FCCO 1998
- AARD 2025
- Fundamental
- Price
- FCCO $22.60
- AARD $11.13
- Analyst Decision
- FCCO Strong Buy
- AARD Strong Buy
- Analyst Count
- FCCO 2
- AARD 4
- Target Price
- FCCO $30.00
- AARD $31.25
- AVG Volume (30 Days)
- FCCO 26.1K
- AARD 31.4K
- Earning Date
- FCCO 07-23-2025
- AARD 08-14-2025
- Dividend Yield
- FCCO 2.65%
- AARD N/A
- EPS Growth
- FCCO 37.48
- AARD N/A
- EPS
- FCCO 1.98
- AARD N/A
- Revenue
- FCCO $67,933,000.00
- AARD N/A
- Revenue This Year
- FCCO $18.61
- AARD N/A
- Revenue Next Year
- FCCO $11.88
- AARD N/A
- P/E Ratio
- FCCO $11.42
- AARD N/A
- Revenue Growth
- FCCO 16.46
- AARD N/A
- 52 Week Low
- FCCO $16.06
- AARD $4.88
- 52 Week High
- FCCO $27.96
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- FCCO 40.95
- AARD N/A
- Support Level
- FCCO $21.80
- AARD N/A
- Resistance Level
- FCCO $23.61
- AARD N/A
- Average True Range (ATR)
- FCCO 0.53
- AARD 0.00
- MACD
- FCCO -0.12
- AARD 0.00
- Stochastic Oscillator
- FCCO 39.22
- AARD 0.00
About FCCO First Community Corporation
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are; Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.